Pharmaceuticals

Imfinzi (durvalumab) Market Forecast 2026–2035: How to Leverage Market Growth

March 5, 2026March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the imfinzi (durvalumab) market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Imfinzi (durvalumab) Market in 2026, and what figure is it projected to hit by 2030?

The imfinzi (durvalumab) market size has experienced rapid expansion over recent years. It is anticipated to expand from $3.01 million in 2025 to $3.36 million in 2026, achieving a compound annual growth rate (CAGR) of 11.4%. The upward trend observed historically can be credited to the clinical achievements of immune checkpoint inhibitors, the increasing prevalence of lung cancer, approvals from regulatory bodies in oncology, enhanced survival outcomes, and robust pharmaceutical investment.

The market for imfinzi (durvalumab) is projected to experience substantial growth over the coming years. This market is anticipated to reach $5.11 million by 2030, exhibiting a compound annual growth rate (CAGR) of 11.1%. Factors contributing to this growth during the forecast period include the broadening of its use into new cancer indications, improved access to immunotherapy, an increase in oncology clinical trials, greater healthcare spending on oncology, and the creation of new combination treatment protocols. Key trends expected during this period involve the increasing uptake of PD-L1 inhibitors, the wider application of immunotherapy in lung cancer, the development of more combination immuno-oncology regimens, a heightened emphasis on biomarker-guided therapies, and its expanded application across various solid tumors.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp

Which Drivers Are Affecting Market Participation In The Imfinzi (durvalumab) Market?

The increasing prevalence of cancer is anticipated to fuel the expansion of the Imfinzi (durvalumab) market moving forward. Cancer encompasses a range of illnesses marked by the uncontrolled multiplication and dispersion of abnormal cells throughout the body, capable of invading and destroying healthy tissues. This rise in cancer cases is largely attributed to an aging global population, as cancer risk escalates with age, alongside lifestyle elements such as smoking, inadequate diet, and obesity, all contributing to higher cancer rates. Durvalumab (Imfinzi) functions as a cancer treatment by inhibiting the PD-L1 protein, thereby preventing cancer cells from avoiding detection by the immune system. For example, data from May 2024 by the National Cancer Institute (NIH), a US-based government agency, indicated that in 2022, there were 18.1 million cancer survivors in the U.S., a figure projected to increase to 22.5 million by 2032. Consequently, the rising incidence of cancer is a key driver for the growth of the Imfinzi (durvalumab) market. Imfinzi (durvalumab) Market Driver: The Rise Of Personalized Medicine Fueling Growth In The Imfinzi (durvalumab) Market

What Segment Categories Are Covered In The Imfinzi (durvalumab) Market?

The imfinzi (durvalumab) market covered in this report is segmented –

1) By Type: 2.4mL Injection, 10mL Injection

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications

Which Competitive Trends Are Impacting The Structure Of The Imfinzi (durvalumab) Market?

Key companies active in the Global Imfinzi (durvalumab) market are prioritizing the expansion of indications, such as perioperative use combined with chemotherapy, to enhance their competitive standing. For example, in January 2023, AstraZeneca plc, a UK based biopharmaceutical company, revealed that IMFINZI plus chemotherapy more than doubled the pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers compared to chemotherapy alone. This regimen involved a two-phase treatment (pre surgery and post surgery) and exhibited a lasting immune activation benefit. This move into gastrointestinal cancer treatments highlights AstraZeneca’s approach to expand its clinical presence and foster enduring product uptake. Nonetheless, this strategy also introduces regulatory challenges, as these more elaborate treatment plans demand supplementary trial data and health economic validation.

Which Leading Companies Dominate The Imfinzi (durvalumab) Market Share?

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

How Does The Imfinzi (durvalumab) Market Perform Across Major Global Regions?

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Imfinzi (durvalumab) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp

Browse Through More Reports Similar to the Global Imfinzi (durvalumab) Market 2026, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795